首頁 > 市場調查報告書 > 製藥

糖尿病神經疾病

糖尿病神經病變市場規模、佔有率和成長分析（按疾病類型、藥物類別、通路和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1899711

糖尿病神經病變市場規模、佔有率和成長分析（按疾病類型、藥物類別、通路和地區分類）－2026-2033年產業預測

Diabetic Neuropathy Market Size, Share, and Growth Analysis, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy), By Drug Class (Capsaicin, Opioid), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，糖尿病神經病變市場規模將達到 41.4409 億美元，到 2025 年將達到 44.3003 億美元，到 2033 年將達到 75.5489 億美元，預測期（2026-2033 年）的複合年成長率為 6.9%。

糖尿病神經病變是一種以長期高血糖引起的神經損傷為特徵的疾病，對糖尿病患者，尤其是長期糖尿病患者而言，構成重大挑戰。雖然初期症狀可能不明顯，但隨著時間的推移，神經損傷的風險會逐漸增加。遺憾的是，目前尚無治癒方法，但已建立了多種治療方法來控制和預防疾病。由於該疾病的複雜性，任何新產品或治療方案都必須受到監管。鑑於糖尿病神經病變的高發生率，尤其是在糖尿病患者中，醫療保健市場正在湧現出巨大的成長機會。隨著人們對該疾病的認知不斷提高，以及對有效管理措施的需求不斷成長，預計糖尿病神經病變管理領域的市場發展和創新將會不斷湧現。

糖尿病神經病變市場促進因素

糖尿病神經病變市場受到糖尿病盛行率不斷上升的顯著影響，這推動了對有效治療方法和管理方案的需求。此外，肥胖、冠狀動脈心臟病和其他糖尿病相關併發症盛行率的上升也促進了市場成長。都市化也發揮關鍵作用，促使人們養成久坐不動的生活方式，其特徵是高碳水化合物攝取和體力活動減少。這些相互關聯的健康挑戰不僅凸顯了對更好治療方法的需求，也為糖尿病神經病變市場的擴張創造了有利環境，因為醫療保健系統正努力滿足受影響人群的需求。

限制糖尿病神經病變市場的因素

糖尿病神經病變市場面臨諸多限制因素，阻礙其成長。治療藥物成本不斷上漲，以及替代療法的興起，都加劇了市場挑戰。其他治療方案，例如放射線治療和物理療法，因其舒適性和有效性更高，可能促使消費者更傾向於選擇這些替代療法而非傳統藥物。此外，嚴格的監管準則、潛在的產品召回、監管核准流程的延誤以及其他相關複雜因素，都構成了市場准入和擴張的壁壘，進一步限制了市場發展。

糖尿病神經病變市場趨勢

隨著創新技術和新型治療方案的蓬勃發展，糖尿病神經病變市場正經歷劇烈的變革。各公司積極探索先進的產品研發，例如經皮貼片、漱口水和特殊外用製劑，以提高治療效果。先進給藥系統的引入，包括無針注射器，正在解決藥物給藥的現有難題，並進一步激發人們對該領域的關注。這種創新驅動力，加上對替代給藥途徑（從口服和經皮到腸外和吸入）日益成長的需求，正在推動市場擴張，並改變糖尿病神經病變的治療模式。

辣椒素
鴉片類藥物
- 氫可酮
- 其他
非類固醇消炎劑（NSAIDs）
- Ibuprofen
- 萘普生
抗憂鬱症
- 三環抗憂鬱藥物（TCAs）
- 阿米替林
- 丙咪嗪
- 正腎上腺素再回收抑制劑（SNRIs）
- Duloxetine
- 選擇性血清素再回收抑制劑（SSRIs）
- 西酞普蘭
- 帕羅西汀
- 抗驚厥藥
- Gabapentin
- Pregabalin
- 托吡酯
其他

全球糖尿病神經病變市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

醫院藥房
零售藥房

全球糖尿病神經病變市場規模及複合年成長率（2026-2033）

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較

主要企業簡介

Abbott Laboratories
Eli Lilly and Company
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Lupin Pharmaceuticals, Inc.
Astellas Pharma US, Inc.
Bayer AG
Teva Pharmaceutical Industries Ltd.
NeuroMetrix Inc.
Helixmith Co., Ltd.
Johnson & Johnson Services, Inc.
Daiichi Sankyo Company, Limited
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics, Inc.
Alfasigma USA, Inc.
ExeGi Pharma LLC

結論與建議

簡介目錄

Product Code: SQMIG35I2245

Diabetic Neuropathy Market size was valued at USD 4144.09 Million in 2024 and is poised to grow from USD 4430.03 Million in 2025 to USD 7554.89 Million by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

Diabetic neuropathy, a nerve-damaging condition linked to prolonged hyperglycemia, poses significant challenges for patients, particularly those with long-standing diabetes. While early symptoms may be subtle, the risk of widespread nerve damage increases over time. Unfortunately, there is currently no cure; however, management and prevention techniques are available through various therapeutic approaches. The complexity of this condition necessitates regulatory oversight for new products and treatment options. This creates substantial growth opportunities for companies in the healthcare market, given the high prevalence of diabetic neuropathy predominantly among individuals with diabetes. As awareness of the condition increases and the demand for effective management options expands, businesses can expect to see significant market advancements and innovations in tackling diabetic neuropathy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Neuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Neuropathy Market Segments Analysis

Global Diabetic Neuropathy Market is segmented by disorder type, drug class, distribution channel and region. Based on disorder type, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Based on drug class, the market is segmented into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDS), antidepressants and other. Based on distribution channel, the market is segmented into hospitals pharmacies and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Neuropathy Market

The diabetic neuropathy market is significantly influenced by the increasing incidence of diabetes, which is driving demand for effective treatments and management solutions. Additionally, the rising prevalence of obesity, coronary heart disease, and other complications related to diabetes contribute to market growth. Urbanization also plays a critical role, as it encourages sedentary lifestyles characterized by high carbohydrate intake and reduced physical activity levels. These interconnected health challenges not only highlight the urgency for better therapeutic options but also foster an environment conducive to the expansion of the diabetic neuropathy market as healthcare systems strive to address the needs of affected populations.

Restraints in the Diabetic Neuropathy Market

The Diabetic Neuropathy market faces several constraints that hinder its growth. Increasing medication costs for treating this condition, along with the rise of alternative therapies, contribute to the challenges within the market. The availability of other treatment options, such as radiotherapy and physiotherapy, often perceived as more comfortable and effective, may lead consumers to prefer these alternatives over traditional medications. Additionally, the market's development is further restricted by strict regulatory guidelines, potential product recalls, delays in the approval process from authorities, and other related complications that create barriers to entry and expansion.

Market Trends of the Diabetic Neuropathy Market

The diabetic neuropathy market is witnessing a dynamic shift as innovative technologies and novel therapeutic solutions gain momentum. Companies are actively exploring the development of advanced products like transdermal patches, mouthwashes, and specialized topical solutions to enhance treatment efficacy. The introduction of sophisticated medication delivery systems, including syringe-free injection devices, addresses existing challenges in pharmaceutical administration, further propelling interest in this sector. This drive for innovation, combined with a growing demand for alternative drug delivery methods-ranging from oral and transdermal to parenteral and inhalation routes-is fueling market expansion and transforming the landscape of diabetic neuropathy management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Diabetic Neuropathy Market Size by Disorder Type & CAGR (2026-2033)

Market Overview
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

Global Diabetic Neuropathy Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Capsaicin
Opioid
- Morphine
- Others
Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
- Ibuprofen
- Naproxen
Antidepressants
- Tricyclic Antidepressants (Tcas)
- Amitriptyline
- Imipramine
- Serotonin And Norepinephrine Reuptake Inhibitors (Snris)
- Duloxetine
- Selective Serotonin Reuptake Inhibitors (Ssris)
- Citalopram
- Paroxetine
- Anticonvulsant Drugs
- Gabapentin
- Pregabalin
- Topiramate
Other

Global Diabetic Neuropathy Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospitals Pharmacies
Retail Pharmacies

Global Diabetic Neuropathy Market Size & CAGR (2026-2033)

North America (Disorder Type, Drug Class, Distribution Channel)
- USA
- Canada
Europe (Disorder Type, Drug Class, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disorder Type, Drug Class, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disorder Type, Drug Class, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Disorder Type, Drug Class, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma US, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeuroMetrix Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Helixmith Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akcea Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alfasigma USA, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ExeGi Pharma LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments